What happened

Teledoc Health (NYSE:TDOC) stock jumped 11.4% in September, according to data from S&P Global Market Intelligence . (It gave back those gains, however, in the first week of October. Shares dropped 12.2% last week, a period in which high-flying growth stocks, particularly in the tech realm, were hit hard.)

So far in 2018, the telehealth service provider's shares have posted a super-healthy gain of 118%, versus the S&P 500's 9.5% return.

Person in lab coat typing on a laptop.

Image source: Getty Images.

So what

Teledoc Health didn't release any notable financial or business data during September, nor were there any significant news reports about it. So it's probably safe to assume that the stock's robust performance was simply a continuation of the upward trend it's been charting for some time thanks to the company's continued strong growth.

In early August, Teledoc delivered second-quarter results that pleased the market. Revenue soared 112% year over year to $94.6 million, a result partly attributable to the company's acquisitions of Best Doctors and Advance Medical. Organic revenue (which excludes the contributions from acquisitions made within the last year) grew 39%. Net loss widened to $25.1 million, or $0.40 per share, from $15.4 million, or $0.28 per share. This was driven by acquisition costs and the company's expansion into behavioral health. 

Investors shouldn't be concerned that Teledoc is posting losses, as that's typical for companies that are relatively new to the public markets (Teledoc IPOed in July 2015) and are investing heavily in growth initiatives. A notable positive on the profitability front is that adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) came in at $2.7 million, compared to a loss of $5.1 million in the year-ago quarter. 

Key metrics moved in the right direction in Q2:

  • Total paid memberships grew 48% year over year to 22.5 million.
  • Total visits surged 72% to 533,000.

Now what

For the full year, the company's guidance is as follows:

  • Revenue: Between $405 million and $410 million. At the midpoint, this represents growth of 75% over 2017.
  • EBITDA: A loss of between $36 million and $40 million. At the midpoint, this represents a 46% narrowing from 2017's loss. 
  • Adjusted EBITDA: $11 million to $13 million. At the midpoint, this represents growth of 400%.
  • Loss per share: $1.48 to $1.52. At the midpoint, this represents a 22% narrowing from last year's loss of $1.93. 

Beth McKenna has no position in any of the stocks mentioned. The Motley Fool recommends Teladoc. The Motley Fool has a disclosure policy.